Gilead Sciences, Inc. $GILD Holdings Lowered by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% during the fourth quarter, Holdings Channel reports. The firm owned 198,000 shares of the biopharmaceutical company’s stock after selling 18,000 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Gilead Sciences were worth $24,303,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Financial Consulate Inc. raised its holdings in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. raised its holdings in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares in the last quarter. MTM Investment Management LLC raised its holdings in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares in the last quarter. Finally, BOCHK Asset Management Ltd bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 53,000 shares of company stock valued at $7,075,670. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. TD Cowen boosted their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Truist Financial reiterated a “buy” rating and issued a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Barclays assumed coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price on the stock. Wolfe Research boosted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, Rothschild & Co Redburn dropped their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Stock Up 1.9%

GILD stock opened at $136.22 on Friday. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company’s 50 day simple moving average is $135.43 and its 200-day simple moving average is $134.08. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The firm has a market capitalization of $169.13 billion, a P/E ratio of 18.56 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the previous year, the business earned $1.81 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.